What is the appropriate cross‑titration schedule for switching a 52‑year‑old female from brexpiprazole (Rexulti) 2 mg daily to aripiprazole (Abilify)?

Cross-Titration from Rexulti to Abilify

For a 52-year-old female switching from brexpiprazole (Rexulti) 2 mg daily to aripiprazole (Abilify), use a gradual cross-titration over 14 days: start aripiprazole 10-15 mg daily while simultaneously tapering brexpiprazole down over 2 weeks, then discontinue brexpiprazole completely.

Recommended Switching Strategy

The most appropriate approach is gradual cross-titration based on the pharmacological profiles of these medications 1, 2. Both are dopamine D2 partial agonists with similar receptor profiles, which reduces the risk of withdrawal or rebound symptoms, but cross-titration remains the preferred method.

Specific 14-Day Protocol

Week 1:

• Day 1-7: Start aripiprazole 10-15 mg daily + continue brexpiprazole 2 mg daily
• Begin reducing brexpiprazole to 1 mg daily by day 7

Week 2:

• Day 8-14: Continue aripiprazole 10-15 mg daily + taper brexpiprazole to 0.5 mg, then discontinue by day 14

The target maintenance dose for aripiprazole is 10-15 mg daily, as doses higher than this have not demonstrated superior efficacy in schizophrenia 3.

Evidence Supporting This Approach

Multiple randomized trials have validated three switching strategies for aripiprazole, all showing comparable safety and efficacy 4:

1. Immediate switch with simultaneous discontinuation
2. Immediate aripiprazole start with 2-week taper of prior antipsychotic
3. Gradual up-titration of aripiprazole with simultaneous 2-week taper

The gradual cross-titration method (option 2 or 3) is preferred because it minimizes the period of overlapping antipsychotic administration while reducing risk of symptom exacerbation 1, 2. Studies specifically comparing risperidone-to-aripiprazole switches found that both titrated-dose and fixed-dose strategies were equally safe and effective 5.

Key Pharmacological Considerations

Since both brexpiprazole and aripiprazole are dopamine D2 partial agonists with similar receptor binding profiles, the risk of withdrawal symptoms is lower than switching between agents with different mechanisms 2, 6. However:

• Brexpiprazole has higher serotonin 5-HT1A partial agonism and lower intrinsic activity at D2 receptors compared to aripiprazole
• Aripiprazole has a longer half-life (75 hours) than brexpiprazole (91 hours for brexpiprazole, but functionally similar)
• Both have low risk of hyperprolactinemia, so no prolactin rebound is expected 7

Clinical Monitoring During Switch

Monitor for:

• Akathisia or restlessness (more common with aripiprazole, especially at higher doses)
• Insomnia or activation (aripiprazole can be more activating)
• Psychotic symptom breakthrough (rare with this switch given similar mechanisms)
• Weight and metabolic parameters (both agents are metabolically favorable)

Dosing Adjustments

If the patient experiences significant akathisia or activation on aripiprazole 15 mg:

• Reduce to 10 mg daily (equally effective dose) 3
• Consider temporary use of a beta-blocker (propranolol 10-20 mg BID) for akathisia management

If switching for inadequate efficacy rather than tolerability, consider that aripiprazole 30 mg may be needed in some patients, though 10-15 mg is the evidence-based starting target 3.

Important Caveats

• Minimize the overlap period to reduce polypharmacy exposure 1
• The 2-week cross-titration represents a balance between safety and minimizing dual antipsychotic exposure
• Some patients may tolerate a faster switch (7-10 days), but 14 days is the most studied approach 4
• Avoid extending cross-titration beyond 2-3 weeks unless clinically necessary, as prolonged antipsychotic polypharmacy should be minimized 1, 8